pGM169-GL67A gene therapy (National Heart & Lung Institute)

N/A

Report date: 2024/09/19 15:03:41

Base Information

Drug NamepGM169-GL67A gene therapy (National Heart & Lung Institute)
Drug Alias NamepGM169/GL67A
ClassificationCell and gene therapy > Gene therapy > Plasmid
Mechanisms of ActionCFTR gene transference
TargetsCystic fibrosis transmembrane conductance regulator
Therapy Area/IndicationsCystic Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Heart & Lung InstituteUk Cystic Fibrosis Gene Therapy ConsortiumGenzyme Corp +[4] 
China Registration ClassN/A

Develop Information

Active CompaniesNational Heart & Lung InstituteUk Cystic Fibrosis Gene Therapy ConsortiumGenzyme Corp +[4] 
Inactive CompaniesN/A
Active IndicationsCystic Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A